Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163438 | 0.89 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7451895 | 0.87 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2986982 | 0.86 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7455605 | 0.84 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11555221 | 0.84 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14052509 | 0.83 | SMN1; SMN2 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12575542 | 0.83 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11755425 | 0.78 | CA1 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2541558 | 0.78 | CTSD (0.55) | MAPTKMT2ASMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL15775269 | 0.77 | ABCB1 (0.48) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107382643-B | FeCl3Catalytic synthesis method of amide compounds | 中国人民解放军63975部队 | 2020-11-20 | — | — | CN | disclosed |
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-6972340-B2 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES (US) | 2005-12-06 | — | — | US | disclosed |
| WO-2003072537-A2 | SELECTIVE PROTEIN TYROSINE PHOSPHATATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003020688-A1 | SELECTIVE PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBOTT LABORATORIES | 2002-11-14 | — | — | US | disclosed |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | ABBVIE INC. | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | CA12 3943/4885CA1 4094/4885CA2 1736/4885 |
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | CA12 3806/4885CA1 3771/4885CA2 1607/4885 |
| US-20020169157-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | CA12 3698/4885CA1 2248/4885CA2 1436/4885 |
| US-20020072516-A1 | Selective protein tyrosine phosphatatase inhibitors | PPM1B, PPM1A, PPM1D | CA12 3698/4885CA1 2248/4885CA2 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.